化疗药物体外干预乳腺癌MCF-7细胞株的耐药基因表达  

Expression of MDR1 and BCRP in Breast Cancer Cell Line MCF-7 after Chemotherapeutical Drug Intervention

作　　者：明洁[1] 黄韬[1] 李治 田元[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院乳腺甲状腺中心,武汉430022

出　　处：《华中科技大学学报（医学版）》2008年第2期204-206,210,共4页Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

基　　金：湖北省"十一五"科技攻关重大项目(No.2006AA301A05)

摘　　要：目的体外评价蒽环类及紫杉类化疗药物与乳腺癌耐药相关基因MDR1(多药耐药基因)和BCRP(乳腺癌相关耐药基因)表达的关系。方法利用RT-PCR技术和荧光定量PCR技术检测体外化疗药物干预后乳腺癌细胞株MCF-7的耐药相关基因表达情况。结果蒽环类药物与MDR1基因表达量间有密切关系,随蒽环类药物浓度的增加和作用时间的延长,MDR1基因表达量也随之增加。而蒽环类药物与BCRP基因间及紫杉类药物与MDR1、BCRP间都无明显的量效关系。结论蒽环类药物是MDR1基因编码的p-gp蛋白的特异性底物之一。临床可能通过检测MDR1的表达量较准确的预测蒽环类药物的疗效,并为个体化的选择敏感性药物提供一定的实验依据。Objective To evaluate the correlation between adriamycin, epirubicin, paclitaxel, docetaxel intervention and the expression levels of MDR1 and BCRP in vitro. Methods RT-PCR and fluorescent quantitative RT-PCR were adopted to detect the expression of MDR1 and BCRP in breast cancer cell line MCF-7 cells after chemotherapeutical drug intervention. Results There was significant dose-effect relationship between adriamycin, epirubicin and the expression level of MDR1, but there was no relationship between adriamycin, epirubicin and the expression level of BCRP and the relationship between paclitaxel, docetaxel and the expression level of MDR1 and BCRP. Conclusion Adriamycin and epirubicin are the specific substrates of p-gp which is encoded by MDR1 gene.

关 键 词：乳腺癌MCF-7细胞株 化疗药物 多药耐药基因 乳腺癌相关耐药基因 

分 类 号：R737.9[医药卫生—肿瘤]